Outcomes for patients undergoing transcatheter aortic valve replacement with ascending aorta dilation

Abstract

Background

We aim to compare the short and long-term outcomes for aortic stenosis (AS) patients undergone TAVR with and without ascending aorta dilation (AAD).

Methods

Consecutive patients diagnosed with native severe AS who underwent TAVR from September 2012 to September 2021 were enrolled. They were stratified into the moderate/severe dilation group (greatest ascending aorta width ≥ 45 mm) and the non/mild dilation group. Survival outcomes were illustrated using Kaplan-Meier curves and evaluated with the log-rank test. Data from patients with CT follow-up of >6 months was used to investigate the progression rate of AAD.

Results

The study cohort comprised 556 patients, with a mean age of 75.52 ± 7.30 years. Among them, 107 patients (19.2%) had a moderate/severe AAD (≥45 mm), with an average diameter of 48.58 mm (±2.82). During hospitalization, both groups witnessed two cases of ascending aortic dissection (1.8% vs 0.5%, P = 0.380). The median follow-up duration was 3.92 years (95% CI: 3.79–4.04 years). No deaths were caused by aortic events and no patients experienced a new aortic dissection. The AAD cohort's 4-year all-cause and cardiovascular mortality rates were not significantly different to the non-dilation group's (log-rank test, P = 0.109 and P = 0.698, respectively). Follow-up CT data revealed that the rate of aortic dilation progression in the moderate/severe dilation group was not significantly different from that in the non/mild group (0.0 mm/year, 25–75%th: −0.3-0.2 vs 0.1 mm/year, 25–75%th: -0.3-0.4, P = 0.394).

Conclusion

This study found no significant difference regarding short-term and long-term outcomes in AS patients with/without moderate/severe AAD undergoing TAVR.